Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells

Leukemia

Volumn 25, Issue 2, 2011, Pages 305-312

  Modi, H ^a   Li, L ^a   Chu, S ^a   Rossi, J ^a   Yee, J K ^a   Bhatia, R ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

chronic myelogenous leukemia; gene transfer; leukemia stem cells; signal transduction

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; RED FLUORESCENT PROTEIN; RETROVIRUS VECTOR; SHORT HAIRPIN RNA;

ANTIGEN EXPRESSION; ARTICLE; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 79751528964     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.257     Document Type: Article

References (31)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765-767. (Pubitemid 13224358)
3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 1990; 247: 1079-1082.
4. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocytemacrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829-3840. (Pubitemid 28525209)
5. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55: 401-423. (Pubitemid 37013211)
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417. (Pubitemid 44903745)
7. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti- Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937. (Pubitemid 34525471)
8. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800. (Pubitemid 34534553)
9. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707. (Pubitemid 36857723)
10. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005; 19: 1034-1041. (Pubitemid 40862017)
11. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60. (Pubitemid 46053043)
12. Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK et al. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABLinduced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res 2004; 64: 5322-5331. (Pubitemid 39006552)
13. Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 2007; 67: 7045-7053. (Pubitemid 47105554)
14. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr- Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764-773. (Pubitemid 24057507)
15. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492. (Pubitemid 41039128)
16. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 2004; 24: 4685-4695. (Pubitemid 38668036)
17. Yam PY, Li S, Wu J, Hu J, Zaia JA, Yee JK. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 2002; 5: 479-484. (Pubitemid 34308674)
18. Ramezani A, Hawley TS, Hawley RG. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2000; 2: 458-469.
19. Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541-7547.
20. Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 2007; 109: 5411-5421. (Pubitemid 46890564)
21. Jiang Y, Zhao RC, Verfaillie CM. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 2000; 97: 10538-10543.
22. Gupta P, McCarthy JB, Verfaillie CM. Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells. Blood 1996; 87: 3229-3236. (Pubitemid 26115352)
23. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85: 3636-3645.
24. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185. (Pubitemid 23306031)
25. Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol 2001; 21: 840-853. (Pubitemid 32104732)
26. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 1997; 14: 2367-2372. (Pubitemid 27260729)
27. Gishizky ML, Cortez D, Pendergast AM. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 1995; 92: 10889-10893.
28. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6: 827-837. (Pubitemid 41568732)
29. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z et al. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 2001; 98: 1773-1781.
30. Cheng AM, Saxton TM, Sakai R, Kulkarni S, Mbamalu G, Vogel W et al. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 1998; 95: 793-803. (Pubitemid 29014459)
31. Feller SM, Tuchscherer G, Voss J. High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia. Leuk Lymphoma 2003; 44: 411-427. (Pubitemid 36118830)